PDCD1 and urothelial carcinoma: Interestingly, LAG3, which we found to be upregulated specifically on CD8+ T cells after immunotherapy, was associated with the response to anti-PD-1 immunotherapy within the tumors of patients with urothelial carcinoma [15].